Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

✍ Scribed by Neil P. Shah; John M. Nicoll; Bhushan Nagar; Mercedes E. Gorre; Ronald L. Paquette; John Kuriyan; Charles L. Sawyers

• Book ID: 114413205
• Publisher: Elsevier Science
• Year: 2002
• Tongue: English
• Weight: 275 KB
• Volume: 2
• Category: Article
• ISSN: 1535-6108
• DOI: 10.1016/s1535-6108(02)00096-x